NASDAQ:OREX - Orexigen Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2229 -0.12 (-35.00 %)
(As of 06/25/2018 03:57 AM ET)
Previous Close$0.2229
Today's Range$0.22 - $0.3198
52-Week Range$0.17 - $3.81
Volume3.74 million shs
Average Volume1.16 million shs
Market Capitalization$4.21 million
P/E Ratio-0.03
Dividend YieldN/A
Beta2.46
Orexigen Therapeutics logoOrexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Receive OREX News and Ratings via Email

Sign-up to receive the latest news and ratings for OREX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OREX
CUSIP68616410
Phone858-875-8600

Debt

Debt-to-Equity Ratio-2.75
Current Ratio2.00
Quick Ratio1.71

Price-To-Earnings

Trailing P/E Ratio-0.03
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.71 million
Price / Sales0.12
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book0.06

Profitability

EPS (Most Recent Fiscal Year)($6.92)
Net Income$-24,520,000.00
Net Margins-192.65%
Return on EquityN/A
Return on Assets-68.53%

Miscellaneous

Employees132
Outstanding Shares18,890,000

The Truth About Cryptocurrencies

Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) posted its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.35) EPS for the quarter, beating the consensus estimate of ($2.13) by $0.78. The biopharmaceutical company earned $18.90 million during the quarter, compared to analysts' expectations of $24.20 million. Orexigen Therapeutics's revenue for the quarter was up 170.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.12 earnings per share. View Orexigen Therapeutics' Earnings History.

Who are some of Orexigen Therapeutics' key competitors?

Who are Orexigen Therapeutics' key executives?

Orexigen Therapeutics' management team includes the folowing people:
  • Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)
  • Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)
  • Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)
  • Ms. Monica Forbes, VP & Acting CFO (Age 42)
  • Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53)

Has Orexigen Therapeutics been receiving favorable news coverage?

Media coverage about OREX stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a media sentiment score of 0.19 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.27 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Orexigen Therapeutics' major shareholders?

Orexigen Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (2.83%). View Institutional Ownership Trends for Orexigen Therapeutics.

Which institutional investors are selling Orexigen Therapeutics stock?

OREX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL. View Insider Buying and Selling for Orexigen Therapeutics.

How do I buy shares of Orexigen Therapeutics?

Shares of OREX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Orexigen Therapeutics' stock price today?

One share of OREX stock can currently be purchased for approximately $0.2229.

How big of a company is Orexigen Therapeutics?

Orexigen Therapeutics has a market capitalization of $4.21 million and generates $33.71 million in revenue each year. The biopharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($6.92) on an earnings per share basis. Orexigen Therapeutics employs 132 workers across the globe.

How can I contact Orexigen Therapeutics?

Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected]


MarketBeat Community Rating for Orexigen Therapeutics (OREX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.